Role of imaging in drug development for Parkinson's disease

Author: Brooks, David J

Source: Future Neurology, Volume 1, Number 3, May 2006 , pp. 335-342(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Imaging dopaminergic function with positron emission tomography (PET) and single photon emission computed tomography (SPECT) helps to confirm the presence of parkinsonian disorders and provides a biomarker for monitoring the efficacy of novel neuroprotective and restorative agents. PET and SPECT can reveal how brain dopamine levels are influenced by therapies and also detect loss of serotonergic and cholinergic function. Parkinson's disease is associated with microglial activation, and PET can potentially determine whether this is influenced by anti-inflammatory approaches. Finally, PET can prove whether novel therapeutics reach their intended targets and generate dose–brain receptor occupancy profiles.

Keywords: dose occupancy; drug development; neuroprotection; Parkinson's disease; PET; SPECT

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796708.1.3.335

Affiliations: 1: Imperial College London, MRC Clinical Sciences Centre and Division of Neuroscience, Cyclotron Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Email: david.brooks@csc.mrc.ac.uk

Publication date: 2006-05-01

More about this publication?

Future Neurology provides a forum to address the most important challenges and advances in our understanding of neurological disease, and highlights emerging trends and prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson's disease.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites